Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic to Acquire DNA Nanotech Firm Palamedrix for up to $52.5M

NEW YORK – Proteomics firm SomaLogic said Tuesday that it has signed an agreement to acquire DNA nanotechnology company Palamedrix for as much as $52.5 million.

Under the deal, SomaLogic will pay $35 million at closing, comprising $14 million in cash and $21 million in SomaLogic common stock, and may pay an additional $17.5 million dependent on revenue-based milestones. The transaction is expected to close in the third quarter and is not expected to contribute to SomaLogic's 2022 revenues.

Boulder, Colorado-based SomaLogic said it plans to use San Diego-based Palamedrix's DNA nanotechnology platform to develop the next generation of its SomaScan proteomic platform and that it believes the technology will help it penetrate the biopharma, academic, and diagnostic markets.

Palamedrix, based in San Diego, has developed DNA nanotechnology that allows it to build arrays of DNA biosensors that can measure proteins and other analytes with single-molecule sensitivity.

"This acquisition enhances our future opportunity for growth while allowing SomaLogic to maintain its strong balance sheet," SomaLogic CEO Roy Smythe said in a statement. "It also expands our footprint to San Diego, California, one of the nation’s leading biotechnology centers of excellence as we continue our work to leverage the power of proteomics to positively impact human health."

"Joining SomaLogic allows us to use our leading molecular engineering expertise to contribute to the company’s impressive product roadmap," Palamedrix CEO Shane Bowen said in a statement. "We share a goal of accelerating our technologies into a new era of proteomics-based biomedical research, clinical diagnostics, and precision medicine."

The Palamedrix team will continue to work out of its existing offices and lab space.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.